Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin αvβ3) antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 8, 2003, Pages 1483-1486

  Miller, William H ^a   Manley, Peter J ^a   Cousins, Russell D ^a   Erhard, Karl F ^a   Heerding, Dirk A ^a   Kwon, Chet ^a   Ross, Stephen T ^a   Samanen, James M ^a   Takata, Dennis T ^a   Uzinskas, Irene N ^a   Yuan, Catherine C K ^a   Haltiwanger, R Curtis ^a   Gress, Catherine J ^a   Lark, Michael W ^a   Hwang, Shing Mei ^a   James, Ian E ^a   Rieman, David J ^a   Willette, Robert N ^a   Yue, Tian Li ^a   Azzarano, Leonard M ^a   Salyers, Kevin L ^a   Smith, Brian R ^a   Ward, Keith W ^a   Johanson, Kyung O ^a   Huffman, William F ^a   more..

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,11 DIHYDRO 3 [3 (2 PYRIDINYLAMINO)PROPOXY] 5H DIBENZO[A,D]CYCLOHEPTENE 10 ACETIC ACID; ARYLBUTYRIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; BINDING AFFINITY; CELL MIGRATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; RESTENOSIS; SMOOTH MUSCLE FIBER;

EID: 0037451878     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00102-1     Document Type: Article

References (23)

1. (a) For recent reviews on integrin αvβ3, see: Coleman P.J., Duong L.T. Exp. Opin. Ther. Patents. 12:2002;1009 (b) Hölzemann G. Idrugs. 4:2001;72 (c) Miller W.H., Keenan R.M., Willette R.N., Lark M.W. Drug Disc. Today. 5:2000;397 (d) Duggan M.E., Hutchinson M.E. Exp. Opin. Ther. Patents. 10:2000;1367 (e) Hartman G.D., Duggan M.E. Exp. Opin. Invest. Drugs. 9:2000;1281.
2. (a) For recent reviews on integrin αvβ3, see: Coleman P.J., Duong L.T. Exp. Opin. Ther. Patents. 12:2002;1009 (b) Hölzemann G. Idrugs. 4:2001;72 (c) Miller W.H., Keenan R.M., Willette R.N., Lark M.W. Drug Disc. Today. 5:2000;397 (d) Duggan M.E., Hutchinson M.E. Exp. Opin. Ther. Patents. 10:2000;1367 (e) Hartman G.D., Duggan M.E. Exp. Opin. Invest. Drugs. 9:2000;1281.
3. (a) For recent reviews on integrin αvβ3, see: Coleman P.J., Duong L.T. Exp. Opin. Ther. Patents. 12:2002;1009 (b) Hölzemann G. Idrugs. 4:2001;72 (c) Miller W.H., Keenan R.M., Willette R.N., Lark M.W. Drug Disc. Today. 5:2000;397 (d) Duggan M.E., Hutchinson M.E. Exp. Opin. Ther. Patents. 10:2000;1367 (e) Hartman G.D., Duggan M.E. Exp. Opin. Invest. Drugs. 9:2000;1281.
4. (a) For recent reviews on integrin αvβ3, see: Coleman P.J., Duong L.T. Exp. Opin. Ther. Patents. 12:2002;1009 (b) Hölzemann G. Idrugs. 4:2001;72 (c) Miller W.H., Keenan R.M., Willette R.N., Lark M.W. Drug Disc. Today. 5:2000;397 (d) Duggan M.E., Hutchinson M.E. Exp. Opin. Ther. Patents. 10:2000;1367 (e) Hartman G.D., Duggan M.E. Exp. Opin. Invest. Drugs. 9:2000;1281.
5. (a) For recent reviews on integrin αvβ3, see: Coleman P.J., Duong L.T. Exp. Opin. Ther. Patents. 12:2002;1009 (b) Hölzemann G. Idrugs. 4:2001;72 (c) Miller W.H., Keenan R.M., Willette R.N., Lark M.W. Drug Disc. Today. 5:2000;397 (d) Duggan M.E., Hutchinson M.E. Exp. Opin. Ther. Patents. 10:2000;1367 (e) Hartman G.D., Duggan M.E. Exp. Opin. Invest. Drugs. 9:2000;1281.
6. Miller W.H., Bondinell W.E., Cousins R.D., Erhard K.F., Jakas D.R., Keenan R.M., Ku T.W., Newlander K.A., Ross S.T., Haltiwanger R.C., Bradbeer J., Drake F.H., Gowen M., Hoffman S.J., Hwang S.-M., James I.E., Lark M.W., Lechowska B., Rieman D.J., Stroup G.B., Vasko-Moser J.A., Zembryki D.L., Azzarano L.M., Adams P.C., Salyers K.L., Smith B.R., Ward K.W., Johanson K.O., Huffman W.F. Bioorg. Med. Chem. Lett. 9:1999;1807.
7. Ward K.W., Azzarano L.M., Bondinell W.E., Cousins R.D., Huffman W.F., Jakas D.R., Keenan R.M., Ku T.W., Lundberg D., Miller W.H., Mumaw J.A., Newlander K.A., Pirhalla J.L., Roethke T.J., Salyers K.L., Souder P.R., Stelman G.J., Smith B.R. Drug Metab. Dispos. 27:1999;1232.
8. Drefahl G., Hartmann M., Grosspietsch H. Chem. Ber. 91:1958;755.
9. Orphanopoulos M., Smonu I. Synth. Commun. 1988;833.
10. Node M., Nishide K., Fuji K., Fujita E. J. Org. Chem. 45:1980;4275.
11. R for ethyl (R)-(+)-4-(4-hydroxyphenyl)-3-phenylbutyrate=23.0 min.
12. Tables of crystal data, fractional atomic coordinates, anisotropic thermal parameters for non-hydrogen atoms, bond distances and angles have been included with the deposited supplementary material (deposition number CCDC 186477) sent to the Cambridge Crystallographic Data Centre, Lensfield Road, Cambridge CB2 1EW, United Kingdom. Listings of structure factors are available from the authors upon request.
13. 3 (64%).
14. Miller W.H., Alberts D.P., Bhatnagar P.K., Bondinell W.E., Callahan J.F., Calvo R.R., Cousins R.D., Erhard K.F., Heerding D.A., Keenan R.M., Kwon C., Manley P.J., Newlander K.A., Ross S.T., Samanen J.M., Uzinskas I.N., Venslavsky J.W., Yuan C.C.K., Haltiwanger R.C., Gowen M., Hwang S.-M., James I.E., Lark M.W., Rieman D.J., Stroup G.B., Azzarano L.M., Salyers K.L., Smith B.R., Ward K.W., Johanson K.O., Huffman W.F. J. Med. Chem. 43:2000;22.
15. Hawes E.M., Wibberley D.G. J. Chem. Soc.(C). 315:1966.
16. (a) Duggan, M. E.; Hartman, G. D.; Hoffman, W. F.; Meissner, R. S.; Perkins, J. J.; Askew, B. C.; Coleman, P. J.; Hutchinson, J. H.; Naylor-Olsen, A. M. International Patent Application WO 98/08840, 1998.
17. (b) Duggan M.E., Duong L.T., Fisher J.F., Hamill T.G., Hoffman W.F., Huff J.R., Ihle N.C., Leu C.-T., Nagy R.M., Perkins J.J., Rodan S.B., Wesolowski G., Whitman D.B., Zartman A.E., Rodan G.A., Hartman G.D. J. Med. Chem. 43:2000;3736.
18. i values represent the means of values determined in two to three separate experiments. See: Wong A., Hwang S.M., McDevitt P., McNulty D., Stadel J.M., Johanson K. Mol. Pharm. 50:1996;529.
19. 50 values represent the means of values determined in two experiments in triplicate with an internal standard. Kumar C.S., James I.E., Wong A., Mwang V., Field J.A., Nuthulaganti P., Conner J.R., Eichman C., Ali F., Hwang S.M., Rieman D.J., Drake F.H., Gowen M. J. Biol. Chem. 272:1997;16390.
20. i values represent the means of values determined in two to three separate experiments. See: Ali F.E., Bennett D.B., Calvo R.R., Elliott J.D., Hwang S.-M., Ku T.W., Lago M.A., Nichols A.J., Romoff T.T., Shah D.H., Vasko J.A., Wong A.S., Yellin T.O., Yuan C.-K., Samanen J.M. J. Med. Chem. 37:1994;769.
21. Pharmacokinetic parameters were determined using non-compartmental analysis of plasma concentration of test compound versus time data determined in three rats. Oral bioavailability was calculated from the dose-normalized iv and po. AUC values, where AUC is the area under the plasma concentration versus time curve. See: Gibaldi, M., Perrier, D. In Pharmacokinetics, 2nd ed.; Swarbrick, J., Ed.; Marcel Dekker: New York, 1982; Vol. 15, pp 145-198.
22. Keenan R.M., Miller W.H., Barton L.S., Bondinell W.E., Cousins R.D., Eppley D.F., Hwang S.-M., Kwon C., Lago M.A., Nguyen T.T., Smith B.R., Uzinskas I.N., Yuan C.C.K. Bioorg. Med. Chem. Lett. 9:1999;1801.
23. See: Yue T.L., Wang S.K., Song C.P., Olson B., Mckenna P.J., Feuerstein G.Z. Circ. Res. 75:1994;1.